You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Managing Patients With Recent Worsening HF With Reduced Ejection Fraction: Keys to Successful Outcomes

  • Authors: John R. Teerlink, MD; Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC; Barry H. Greenberg, MD; Scott D. Solomon, MD; Jane E. Wilcox, MD, MSc
  • CME Released: 12/22/2022
  • Valid for credit through: 12/22/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.50 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity was developed for clinicians who manage patients with heart failure (HF).

The goals of this program are for clinicians to:

  • Recognize the need for development and utilization of new HF therapies in patients with worsening HF (WHF) and reduced ejection fraction (EF)
  • Identify the potential roles for vericiguat and omecamtiv mecarbil in the management of patients with HFrEF
  • Reduce the risk for re-hospitalization and mortality by implementing effective transition of care strategies and communicating fundamental features of patient self-care
  • Indicate the importance of personalizing treatment tailored to the different phenotypes of HFrEF patients and incorporating shared decision-making

Learning Objectives

Upon completion of this activity, participants will:

  • Describe the characteristics and outcomes associated with patients with WHF and reduced EF
  • Interpret the evidence from clinical studies of new and emerging therapies in patients with HFrEF who have experienced a recent WHF event
  • Indicate key elements of effective transitions of care for patients with HF
  • Discuss the complexity of implementation of guideline-directed medical therapy (GDMT) in patients with HFrEF


Disclosures

Disclosures

Voxmedia strives to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored educational activities. All prospective faculty are required to disclose to Voxmedia all financial relationships for the preceding 24 months (1) with any commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity or developing content. Only after Voxmedia mitigates all financial relationships may faculty receive approval to participate, and are expected to contribute evidence-based material. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis. All information submitted will be peer-reviewed. The intent of this disclosure is not to prevent faculty from participating, but rather to provide learners with information on which they can make their own judgment of commercial bias. Voxmedia will disclose to learners that all relevant financial relationships have been mitigated in either written materials, visually and/or verbally. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation. Speakers must make a meaningful disclosure to the audience of their discussions of any unlabeled or investigational use(s) of drugs or devices.


Chair

  • John R. Teerlink, MD

    Professor of Medicine
    University of California, San Francisco School of Medicine
    Director of Heart Failure
    San Francisco Veterans Affairs Medical Center
    San Francisco, California

    Disclosures

    John R. Teerlink, MD, has the following relevant financial relationships:
    Consultant: 3ive Labs; Abbott; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cytokinetics; Medtronic; Merck; Novartis; Verily; ViCardia; Windtree Therapeutics
    Contracted Research: Abbott; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cardurion; Cytokinetics; EBR Systems; Medtronic; Novartis; ViCardia; Windtree Therapeutics

Faculty

  • Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC

    Associate Chief Nursing Officer
    Cleveland Clinic
    Cleveland, Ohio

    Disclosures

    Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC, has the following relevant financial relationships:
    Consultant: Abiomed; American Regent; AstraZeneca; Boehringer Ingelheim; Boston Scientific; Cytokinetics; Eli Lilly; Merck
    Research support from: AstraZeneca; Novartis
    Speaker: Merck

  • Barry H. Greenberg, MD

    Distinguished Professor of Medicine
    Director, Advanced Heart Failure Treatment Program
    University of California San Diego
    La Jolla, California

    Disclosures

    Barry H. Greenberg, MD, has the following relevant financial relationships:
    Grants/Research Support: Rocket Pharma
    Consultant: AstraZeneca; Bayer; Ionis; Merck; Tenaya
    Honorarium: ACI; Axon; Bayer; Boehringer Ingelheim; Cytokinetics; EBR Systems; Impulse Dynamics; Ionis; Merck; Mesoblast; Vifor; Viking; Windtree Therapeutics

  • Scott D. Solomon, MD

    The Edward D. Frohlich Distinguished Chair
    Professor of Medicine
    Harvard Medical School
    Brigham and Women’s Hospital
    Boston, Massachusetts

    Disclosures

    Scott D. Solomon, MD, has the following relevant financial relationships:
    Consultant: Abbott; Action; Akros; Alnylam; American Regent; Amgen; Anacardio; Arena; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cardior; Cardiac Dimensions; Cardurion; CellProThera; Corvia; Cytokinetics; Daiichi-Sankyo; Dinaqor; GSK; Janssen; Lexicon; Lilly; Merck; Moderna; Myokardia; Novartis; Puretech Health; Quantum Genomics; Roche; Sanofi-Pasteur; Sarepta; Tenaya; Theracos; Tremeau
    Research grants from: Actelion; Alnylam; Amgen; AstraZeneca; Bayer; Bellerophon; Bristol Myers Squibb; Celladon; Cytokinetics; Eidos; Gilead; GSK; Ionis; Lilly; Mesoblast; MyoKardia; NIH/NHLBI; Neurotronik; Novartis; Novo Nordisk; Respicardia; Sanofi Pasteur; Theracos; US2.AI

  • Jane E. Wilcox, MD, MSc

    Associate Professor of Medicine
    Chief, Section of Heart Failure Treatment and Recovery
    Northwestern University Feinberg School of Medicine
    Chicago, Illinois

    Disclosures

    Jane E. Wilcox, MD, MSc, has the following relevant financial relationships:
    Consultant: Abbott; Abiomed; Amgen; AstraZeneca; Boehringer Ingelheim; Cytokinetics; Norvartis

Voxmedia

  • John F. Kocsis, PhD

    President
    Hazlet, New Jersey

    Disclosures

    John F. Kocsis, PhD, has no relevant financial relationships.


Accreditation Statements


Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    For Physicians

  • Voxmedia designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact this provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of  80%  on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Managing Patients With Recent Worsening HF With Reduced Ejection Fraction: Keys to Successful Outcomes

Authors: John R. Teerlink, MD; Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC; Barry H. Greenberg, MD; Scott D. Solomon, MD; Jane E. Wilcox, MD, MScFaculty and Disclosures

CME Released: 12/22/2022

Valid for credit through: 12/22/2023

processing....

Learning Feedback Question

Before you begin, please take this brief survey.

  • Print